Cardiology

Patients with ASCVD experienced a more significant reduction in LDL-C.

This approval marks the availability of the first near-complete stabilizer of transthyretin.

Results of a study at the Veterans Health Administration found that feedback and education led to better medication outcomes for patients.

Study results are especially important for women, who are more likely to experience heart failure with mildly reduced or preserved ejection fraction.

A PDUFA date for acoramidis has been set for November 29, 2024.

High copayments can be a structural barrier to medication therapy adherence.

In a comprehensive literature review, researchers addressed the impact cardiac surgery has on gastrointestinal outcomes.

Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

The Heart Failure Society of America 2024 Annual Meeting featured presentations exploring the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for patients with heart failure.

Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Vaccination against respiratory viruses such as RSV and the flu are crucial to prevent adverse outcomes in patients with heart failure.

Left ventricular ejection fraction, brain natriuretic peptide, and heart failure-related hospitalizations were among the improved metrics.

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

Researchers analyzed the outcomes of positive airway pressure therapy for Medicare beneficiaries with obstructive sleep apnea.

A recent meta-analysis found that supplementing with vitamin D could improve blood pressure, blood lipid levels, and glycemic parameters.

Data from the SELECT clinical trial were analyzed to evaluate the role of semaglutide therapy on all-cause, cardiovascular, and non-cardiovascular mortality during the COVID-19 pandemic.

Findings were presented at the American Heart Association's Hypertension Scientific Sessions in Chicago, Illinois.

Additional data will be presented at a scientific meeting later this year.

Final approval of the therapy may occur after expiration of the 3-year regulatory exclusivity for Tyvaso DPI on May 23, 2025.

Finerenone (Kerendia) was previously approved in 2021 to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease associated with type 2 diabetes.

As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.